Study design and participants
pleural effusion, ascites, pneumonitis, arrhythmia, interstitial pulmonary disease, cancer, gastric neuroendocrine tumors, acute pulmonary disease, pericardial effusion, infection, pulmonary hypertension, Cancer
SYSTEMIC DISEASE, SQUAMOUS CELL SKIN CANCER, ARRHYTHMIA, GASTROINTESTINAL OBSTRUCTION, SUPERFICIAL BLADDER CANCER, CANCER, ASCITES, PULMONARY FIBROSIS, INTERSTITIAL PULMONARY DISEASE, BREAST CANCER, CANCER, CARDIOVASCULAR DISEASES, INFECTION, CONGESTIVE HEART FAILURE, PULMONARY HYPERTENSION, PNEUMONITIS, METASTASIS, MYOCARDIAL INFARCTION, CERVICAL CANCER, ASYMPTOMATIC CORONARY HEART DISEASE
The SHARED study (ChiCTR1900024428) followed the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the ethics committees of the Comprehensive Cancer Centre of Drum Tower Hospital (2019-093-02) and other participating centers. All patients provided written informed consent before any procedure.This study was a multicenter, single-arm phase 2 trial conducted at three centers in China (The date of registration was July 11, 2019, Patients with gastric neuroendocrine tumors, distant metastasis, uncontrolled pleural effusion, pericardial effusion, ascites, history of chemotherapy, radiotherapy, or immunotherapy, history of cancer within the past 5 years (except basal cell or squamous cell skin cancer, superficial bladder cancer, in-situ cervical cancer, or in-situ breast cancer), gastrointestinal obstruction, uncontrolled infection, uncontrolled systemic disease, or the use of immunosuppressive agents or experimental drugs in the past 4 weeks were excluded. Patients with severe cardiovascular diseases, such as symptomatic coronary heart disease, grade II congestive heart failure, uncontrolled arrhythmia and myocardial infarction, occurred within 12 months before admission; or with a history of interstitial pulmonary disease, non-infectious pneumonitis, pulmonary fibrosis, and acute pulmonary disease; or respiratory condition that required any oxygen supplementation, active pneumonitis and clinically significant pulmonary hypertension occurred within 12 months before admission were excluded. Pregnant, breastfeeding, or pregnancy test-positive women were also excluded